No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
COSM240719P2500
- 1.15
- +0.05+4.55%
15min DelayClose Jul 19 15:58 ET
1.26High1.15Low
1.26Open1.10Pre Close12 Volume61 Open Interest2.50Strike Price1.50KTurnover0.00%IV-8.87%PremiumJul 19, 2024Expiry Date1.26Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.06Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Express News | Cosmos Health Inc - Regains Compliance With Nasdaq Minimum Bid Price Rule
Cosmos Health Regains Nasdaq Compliance
Cosmos Health (COSM) said it has regained compliance with Nasdaq's minimum bid price rule for continued listing on the exchange.The company said it was notified by Nasdaq that it achieved a closing
Cosmos Health Regains Compliance With Nasdaq Minimum Bid Price Rule
CHICAGO, IL / ACCESSWIRE / July 19, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D,
Express News | Cosmos Health Shares Are Trading Higher After the Company Announced Its Subsidiary, Cana Laboratories, Secured Additional Contract Manufacturing Agreements With Provident Pharmaceuticals
Cosmos Health's Cana Secures Additional Contract Manufacturing Agreement With Provident Pharmaceuticals for 700,000 Units, Bringing Total Order Book to 5.02 Million Units
CHICAGO, IL / ACCESSWIRE / July 18, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D,
Express News | Cosmos Health Announces Successful Completion Of Pilot Production And Scale-Up Phases Of CCX0722, A Biocompatible Hydrogel For Weight Management
Comments
$Cosmos Health(COSM.US$ Cosmos Health's Cana Secures Additional Contract Manufacturing Agreement With Provident Pharmaceuticals for 700,000 Units, Bringing Total Order Book to 5.02 Million Units
5
thank you!
. You’re very welcome 🩷
$Cosmos Health(COSM.US$
Cosmos Health's Cana Secures Additional Contract Manufacturing Agreement with Provident Pharmaceuticals for 700,000 Units, Bringing Total Order Book to 5.02 Million Units
Cosmos Health (NASDAQ:COSM) announced that its subsidiary, Cana Laboratories, has secured additional contract manufacturing agreements with Provident Pharmaceuticals. The new orders include:
408,000 units of MIOREL for muscle spasms
222,000 units of CALCIFOLIN for nucleic acid synthesis
72,000 units...
Cosmos Health's Cana Secures Additional Contract Manufacturing Agreement with Provident Pharmaceuticals for 700,000 Units, Bringing Total Order Book to 5.02 Million Units
Cosmos Health (NASDAQ:COSM) announced that its subsidiary, Cana Laboratories, has secured additional contract manufacturing agreements with Provident Pharmaceuticals. The new orders include:
408,000 units of MIOREL for muscle spasms
222,000 units of CALCIFOLIN for nucleic acid synthesis
72,000 units...
1
$Cosmos Health(COSM.US$
Cosmos Health Advances Commercialization of CCX0722 Weight Management Solution with Completion of Pilot Production and Scale-Up Phases; Significant Step Towards Entering $143Bn Global Market
Cosmos Health (NASDAQ:COSM) announced the successful completion of the pilot production and scale-up phases for its weight management solution, CCX0722, a biocompatible hydrogel. These milestones mark the end of the development phase, following earlier project updates such as the...
Cosmos Health Advances Commercialization of CCX0722 Weight Management Solution with Completion of Pilot Production and Scale-Up Phases; Significant Step Towards Entering $143Bn Global Market
Cosmos Health (NASDAQ:COSM) announced the successful completion of the pilot production and scale-up phases for its weight management solution, CCX0722, a biocompatible hydrogel. These milestones mark the end of the development phase, following earlier project updates such as the...
2
Read more